At a glance
- Originator GlaxoSmithKline
- Class Antibacterials
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory tract infections
Most Recent Events
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 30 Sep 2000 Discontinued-Preclinical for Respiratory tract infections in United Kingdom (Unknown route)
- 26 Sep 2000 New profile